Ibrutinib, the first‐generation covalent BTK inhibitor, is commonly used in the treatment of CLL and has been associated with increased rates of cardiovascular adverse events (CVAEs) [8, 9, 10, 11, 12]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.